KDR and glioblastoma: Unfortunately, the use of bevacizumab in clinical treatment did not significantly prolong the survival time of newly diagnosed GBM patients, and anti-VEGFR2 therapy alone often has only short-term effects, which may be closely related to excessive vascular pruning and lack of T-cells in the TME [12, 35].